PURPOSE: Exercise intolerance, evaluated by O2 consumption, predicts mortality in cystic fibrosis (CF). People with CF exhibit skeletal muscle dysfunctions that may contribute to an imbalance between O2 delivery and utilization. Sildenafil, a phosphodiesterase type 5 inhibitor, increases blood flow and improves O2 consumption, although the exact mechanisms in CF have yet to be elucidated. Thus, we hypothesized that exercise intolerance in CF is limited primarily by an impaired skeletal muscle O2 utilization, and sildenafil improves exercise tolerance in CF by addressing this mismatch between O2 demand and extraction. METHODS: Fifteen individuals with mild to moderate CF and 18 healthy controls completed an incremental exercise test and measurements of gaseous exchange, chronotropic response, hemodynamics, and O2 extraction and utilization. People with CF also completed a 4-wk treatment with sildenafil with a subsequent follow-up evaluation after treatment. RESULTS: Skeletal muscle O2 extraction and utilization during exercise were reduced in people with CF when compared with controls. Exercise capacity in our CF population was minimally limited by hemodynamic or chronotopic responses, whereas peripheral O2 extraction was more closely associated with exercise capacity. The study also demonstrated that 4 wk of sildenafil improved skeletal muscle O2 utilization during exercise to similar values observed in healthy individuals. CONCLUSIONS: Individuals with mild to moderate CF exhibit exercise intolerance secondary to a reduction in O2 utilization by the exercising skeletal muscle. The present study demonstrated that 4 wk of sildenafil treatment improves the capacity of the skeletal muscle to use O2 more efficiently during exercise. Findings from the present study highlight the importance of targeting skeletal muscle O2 utilization to improve exercise tolerance in CF.
PURPOSE: Exercise intolerance, evaluated by O2 consumption, predicts mortality in cystic fibrosis (CF). People with CF exhibit skeletal muscle dysfunctions that may contribute to an imbalance between O2 delivery and utilization. Sildenafil, a phosphodiesterase type 5 inhibitor, increases blood flow and improves O2 consumption, although the exact mechanisms in CF have yet to be elucidated. Thus, we hypothesized that exercise intolerance in CF is limited primarily by an impaired skeletal muscle O2 utilization, and sildenafil improves exercise tolerance in CF by addressing this mismatch between O2 demand and extraction. METHODS: Fifteen individuals with mild to moderate CF and 18 healthy controls completed an incremental exercise test and measurements of gaseous exchange, chronotropic response, hemodynamics, and O2 extraction and utilization. People with CF also completed a 4-wk treatment with sildenafil with a subsequent follow-up evaluation after treatment. RESULTS: Skeletal muscle O2 extraction and utilization during exercise were reduced in people with CF when compared with controls. Exercise capacity in our CF population was minimally limited by hemodynamic or chronotopic responses, whereas peripheral O2 extraction was more closely associated with exercise capacity. The study also demonstrated that 4 wk of sildenafil improved skeletal muscle O2 utilization during exercise to similar values observed in healthy individuals. CONCLUSIONS: Individuals with mild to moderate CF exhibit exercise intolerance secondary to a reduction in O2 utilization by the exercising skeletal muscle. The present study demonstrated that 4 wk of sildenafil treatment improves the capacity of the skeletal muscle to use O2 more efficiently during exercise. Findings from the present study highlight the importance of targeting skeletal muscle O2 utilization to improve exercise tolerance in CF.
Authors: Bishnu P Dhakal; Rajeev Malhotra; Ryan M Murphy; Paul P Pappagianopoulos; Aaron L Baggish; Rory B Weiner; Nicholas E Houstis; Aaron S Eisman; Stacyann S Hough; Gregory D Lewis Journal: Circ Heart Fail Date: 2014-10-24 Impact factor: 8.790
Authors: Thomas Radtke; Sarah Crook; Georgios Kaltsakas; Zafeiris Louvaris; Danilo Berton; Don S Urquhart; Asterios Kampouras; Roberto A Rabinovich; Samuel Verges; Dimitris Kontopidis; Jeanette Boyd; Thomy Tonia; Daniel Langer; Jana De Brandt; Yvonne M J Goërtz; Chris Burtin; Martijn A Spruit; Dionne C W Braeken; Sauwaluk Dacha; Frits M E Franssen; Pierantonio Laveneziana; Ernst Eber; Thierry Troosters; J Alberto Neder; Milo A Puhan; Richard Casaburi; Ioannis Vogiatzis; Helge Hebestreit Journal: Eur Respir Rev Date: 2019-12-18
Authors: Helge Hebestreit; Hubertus G M Arets; Paul Aurora; Steve Boas; Frank Cerny; Erik H J Hulzebos; Chantal Karila; Larry C Lands; John D Lowman; Anne Swisher; Don S Urquhart Journal: Respiration Date: 2015-09-09 Impact factor: 3.580
Authors: Mark D Schluchter; Michael W Konstan; Mitchell L Drumm; James R Yankaskas; Michael R Knowles Journal: Am J Respir Crit Care Med Date: 2006-07-20 Impact factor: 21.405
Authors: J L Taylor-Cousar; C Wiley; L A Felton; C St Clair; M Jones; D Curran-Everett; K Poch; D P Nichols; G M Solomon; M T Saavedra; F J Accurso; J A Nick Journal: J Cyst Fibros Date: 2014-11-13 Impact factor: 5.482
Authors: Matthew A Tucker; Nichole Lee; Paula Rodriguez-Miguelez; Jacob Looney; Reva H Crandall; Caralee Forseen; Kathleen T McKie; Ryan A Harris Journal: Eur J Appl Physiol Date: 2018-10-24 Impact factor: 3.078